Baricitinib Lowers Structural Joint Damage in Patients With RA: Study

Published On 2021-10-07 06:00 GMT   |   Update On 2021-10-07 06:05 GMT

Baricitinib helps to reduce structural joint damage in Patients With rheumatoid arthritis (RA), suggests a study published in the Journal of Rheumatology.

A group of researchers from the Netherlands conducted a study to evaluate the effect of baricitinib on inhibiting the radiographic progression of structural joint damage over 5 years in patients with active rheumatoid arthritis (RA). They stated, "Because no cure for RA exists, it is important to reduce a patient's inflammation to the lowest level possible to prevent structural damage from accruing and thereby maintaining patients' functional ability." 

Advertisement

Patients completed 1 of 3 phase 3 baricitinib trials and entered the long-term extension RA-BEYOND, in which patients received once-daily 4 mg or 2 mg baricitinib. Across these trials, patients initially receiving methotrexate (MTX) or adalimumab switched to baricitinib 4 mg at week 52. Patients initially receiving placebo switched to baricitinib 4 mg at week 24. Radiographs were scored at baseline and years 2, 3, 4, and 5. Change from baseline in van der Heijde modified Total Sharp Score (ΔmTSS) was computed.

Advertisement

The results of the study are as follows:

· Overall, 2125/2573 (82.6%) randomized patients entered RA-BEYOND; 1837/2125 (86.4%) entered this analysis.

· From years 3 to 5, higher proportions of DMARD-naïve patients on initial baricitinib (monotherapy; +MTX) had no progression versus initial MTX

· Higher proportions of patients with an inadequate response (IR) to MTX on initial baricitinib or adalimumab versus placebo had no progression

Advertisement

· Higher proportions of patients with conventional synthetic (cs)DMARD-IR on initial baricitinib 4 mg had less progression versus initial placebo or baricitinib 2 mg.

Thus, the researchers concluded that oral baricitinib maintained lower levels of radiographic progression than initial csDMARD or placebo through 5 years in patients with active rheumatoid arthritis (RA).

Reference:

Advertisement

A study titled, "Radiographic progression of structural joint damage over 5 years of baricitinib treatment in patients with rheumatoid arthritis: Results from RA-BEYOND" by Désirée van der Heijde et. al published in the Journal of Rheumatology.

DOI: 10.3899/jrheum.210346


Tags:    
Advertisement
Article Source : Journal of Rheumatology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News